QBIO (Q BioMed) Cyclically Adjusted PS Ratio: (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Q BioMed Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Q BioMed  (OTCPK:QBIO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Q BioMed Cyclically Adjusted PS Ratio Related Terms


Q BioMed Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Q BioMed's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q BioMed Cyclically Adjusted PS Ratio Chart

Q BioMed Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.28

Q BioMed Quarterly Data
May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 3.28 0.00

QBIO vs RGMP, CALA, PPCB: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Q BioMed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q BioMed Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Q BioMed's Cyclically Adjusted PS Ratio falls into.



Q BioMed Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Q BioMed's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Nov22 is calculated as:

For example, Q BioMed's adjusted Revenue per Share data for the fiscal year that ended in Nov22 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Nov22 (Change)*Current CPI (Nov22)
=0.006/297.7110*297.7110
=0.006

Current CPI (Nov22) = 297.7110.

Q BioMed Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201311 0.000 233.069 0.000
201411 0.000 236.151 0.000
201511 0.000 237.336 0.000
201611 0.000 241.353 0.000
201711 0.000 246.669 0.000
201811 0.000 252.038 0.000
201911 0.000 257.208 0.000
202011 0.001 260.229 0.001
202111 0.007 277.948 0.007
202211 0.006 297.711 0.006

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Q BioMed Business Description

Address c/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017
Q BioMed Inc is a biotech acceleration and commercial stage company. It is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The company provides these target assets the strategic resources, developmental support, and expansion capital needed to ensure customers meet their developmental potential, enabling them to provide products to patients in need.